Publication

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

QSP modeling reveals how anti-amyloid therapies impact tau biomarkers and cognitive outcomes in Alzheimer’s disease.

CertaraMay 4, 2026

Poster

Modeling CAR-T Outcomes in Multiple Myeloma

Learn how QSP modeling predicts CAR-T therapy outcomes, identifies patient-specific response drivers, and supports multi-antigen…

CertaraMay 4, 2026

Poster

Modeling T-cell Exhaustion in Immunotherapy

Discover how QSP modeling predicts T-cell exhaustion, relapse risk, and optimal dosing strategies for T-cell…

CertaraMay 4, 2026

Poster

Modeling Hematopoiesis in MDS and AML with QSP

Discover a mechanistic QSP platform model of hematopoiesis to evaluate therapies in MDS and AML,…

CertaraMay 1, 2026

Poster

IO Simulator: A QSP Platform for Immuno-Oncology

This poster showcases how IO Simulator predicts immunotherapy response and supports combination design and biomarker…

CertaraApril 30, 2026

Blog

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Explore Certara’s insights from QSPC 2026, including virtual patients, regulatory adoption, AI in QSP, and…

CertaraApril 28, 2026

Blog

Top 10 Benefits of Simcyp® Simulator for Drug Development

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= April 23, 2026 Physiologically based pharmacokinetic (PBPK) modeling has evolved from an emerging methodology…

CertaraApril 23, 2026

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

CertaraApril 22, 2026

On-Demand Webinar

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

Learn how model-informed strategies support ADC labeling, dose optimization, and market access through integrated evidence…

CertaraApril 10, 2026

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

CertaraApril 7, 2026

Modeling and Simulation

Understanding quantitative effects of anti-amyloid therapies on tau biomarkers and functional outcome

Modeling CAR-T Outcomes in Multiple Myeloma

Modeling T-cell Exhaustion in Immunotherapy

Modeling Hematopoiesis in MDS and AML with QSP

IO Simulator: A QSP Platform for Immuno-Oncology

From Models to Impact: What QSPC 2026 Revealed About the Future of Drug Development

Top 10 Benefits of Simcyp® Simulator for Drug Development

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Extending the Value of Antibody–Drug Conjugates: Model-Informed Labeling, Expansion, and Market Access

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

Newsletter sign up

Quick links

Solutions

Contact